Heron Therapeutics Inc vs Seagate Technology Holdings PLC — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Seagate Technology Holdings PLC trades at $891.81 (market cap $181.56B). The key difference: Seagate Technology Holdings PLC is far larger — about 1985.1× Heron Therapeutics Inc's market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | STX | |
|---|---|---|
Market Cap | $91.46M | $181.56B |
Sector | Health | Technology |
52-Week High | $1.96 | $1.09K |
52-Week Low | $0.39 | $146.59 |
Enterprise Value | $189.36M | $184.59B |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Seagate Technology (STX) trades at $801.81, up 1.89% with strong recent earnings beats and AI-driven storage demand. The stock shows bearish technical signals but benefits from robust fundamentals including 21.6% net margin and 96.27% ROE. Recent analyst upgrades highlight confidence in AI infrastructure growth, though high valuations (P/E 74.73) and negative shareholder equity pose challenges.
Outlook remains positive with AI storage tailwinds and $987.86 consensus price target suggesting 23% upside. Key risks include elevated debt levels (73.31% debt-to-asset ratio) and competitive pressures. The Q2 2026 earnings report on July 28, 2026 will be critical for validating current growth trajectory amid volatile memory markets.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →